Nimbus Therapeutics is a technology company.
Nimbus Therapeutics has raised $438.0M across 8 funding rounds.
Nimbus Therapeutics has raised $438.0M in total across 8 funding rounds.
Nimbus Therapeutics is a clinical-stage biotechnology company specializing in structure-based drug discovery to develop novel small-molecule medicines targeting difficult-to-drug proteins implicated in oncology, immunology, and metabolic diseases.[1][2][3][5] It serves patients with serious conditions like cancer, psoriasis, arthritis, fatty liver disease (including MASH/NASH), and diabetes by designing highly selective, potent drugs—such as those against WRN (in Ph1/2), SIK, ACC, IRAK4, Tyk2, and KRas—that traditional methods couldn't reach due to issues with potency, selectivity, and pharmacokinetics.[1][3][5] The company has advanced three programs into clinical development, with growth momentum shown through 15 years of innovation, a shift from discovery platform to full medicine-maker, and partnerships like Takeda for psoriasis.[2][4]
Headquartered in Cambridge, MA (with Boston listed), Nimbus integrates computational design, chemistry, pharmacology, and collaborators to pioneer a physics-based, computational-first approach ahead of AI trends, maintaining a science-first, patient-focused mission.[2][3][4]
Nimbus Therapeutics traces its roots to around 2010, marking 15 years of operation by 2025, starting as a pioneer in computational drug discovery with a physics-based method that was revolutionary at the time—predating widespread AI use in predictions.[2] The company evolved from a discovery platform to a therapeutics developer, renaming to Nimbus Therapeutics in 2015 to emphasize making medicines for patients.[2] Key leadership includes co-founder and Chairman, alongside executives like CEO, President of R&D, and VPs in chemistry, biology, oncology, and computational areas; the team comprises world-class experts drawn by cutting-edge science and people.[2][4]
Pivotal moments include early traction in computational power for drug design, expanding across therapeutic areas (diabetes, cancer, psoriasis, arthritis, fatty liver), a 2015 liver disease focus (NASH/MASH), and partnerships like Takeda, all while staying true to a nimble, collaborative, curiosity-driven culture named for "radiant light" symbolizing excellence.[2][4]
Nimbus stands out in biotech through these key strengths:
Nimbus rides the wave of precision medicine and computational biology, leveraging structure-based design to tackle validated targets long evading traditional small-molecule drugs amid rising demand for oncology, immunology, and metabolic therapies.[1][3][5] Timing aligns with AI/ML proliferation in drug discovery, but Nimbus's early physics-based computational edge positions it as a leader, influencing the ecosystem by validating "undruggable" proteins and partnering with giants like Takeda to accelerate clinical pipelines.[2][3]
Market forces favor it: aging populations drive disease burdens (e.g., MASH, cancer), while biotech funding prioritizes de-risked, selective assets; Nimbus shapes the landscape by demonstrating scalable, tech-driven paradigms that blend computation with wet-lab execution, inspiring hybrid models in pharma R&D.[2][3][4]
Nimbus is poised to expand its clinical pipeline, with WRN in Ph1/2 and momentum in oncology/immunology/metabolics signaling potential Phase 3 readouts and more INDs via its computational platform.[1][5] Trends like AI-enhanced design and multi-modal therapies will amplify its edge, potentially leading to approvals and big-pharma deals amid MASH/cancer market growth. Its influence may evolve from innovator to category leader, illuminating paths to breakthrough medicines as "science-first" biotech matures—reinforcing its core as a radiant force in patient-centric drugging of the undruggable.[2][4][5]
Nimbus Therapeutics has raised $438.0M in total across 8 funding rounds.
Nimbus Therapeutics's investors include 10100, Access Biotechnology, Atlas Venture, Browder Capital, Gigafund, Krishna Yeshwant, Mithril Capital Management, NEO, Pfizer Venture Investments, Polaris Partners, RA Capital, Sanofi Ventures.
Nimbus Therapeutics has raised $438.0M across 8 funding rounds. Most recently, it raised $130.0M Venture Round in September 2022.